Partner David Plotinsky is featured in an article from Pharma Intelligence’s Scrip covering Committee on Foreign Investment in the United States (CFIUS) clearance of China-related life sciences transactions.
“Given the heightened scrutiny the US Government is now giving to biotechnology and biomanufacturing, it seems reasonable to assume that life sciences deals with a Chinese acquirer should generally be expected to clear CFIUS, if at all, only with mitigation,” David said.
Read the full Scrip article >>
Subscription may be required.